DAPS Study : Denosumab Adherence Preference Satisfaction Study

DAPS Study : Denosumab Adherence Preference Satisfaction Study

• BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab (sequential therapy)

• This contrasts with the results of the Post-FREEDOM study in which subjects who received IV Reclast after denosumab experienced a decline in bone mineral density (BMD).

Infographic

Reference

Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S; DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011 Jun;22(6):1725-35.

>